The University of Southampton
University of Southampton Institutional Repository

Burden of Lassa fever disease in pregnant women and children and options for prevention

Burden of Lassa fever disease in pregnant women and children and options for prevention
Burden of Lassa fever disease in pregnant women and children and options for prevention

Lassa fever is a serious epidemic viral disease in West Africa affecting an estimated 2 million people annually with about 5000–10,000 deaths, although supporting data is sparse. Lassa fever significantly affects neonates, children, and pregnant women, however, comprehensive data on its impact in these populations are lacking. We reviewed the available literature on Lassa fever to assess its prevalence and impact in these populations and implications for vaccine development. Clinical features in children were similar to those observed in adults, with complications such as bleeding. Altered mental status, anasarca (swollen baby syndrome), bleeding, and poor urine output were risk factors for death. The case fatality rate (CFR) in 16 paediatric studies ranged from 6 % to 63 % and was 66.7 % and 75.0 % in two neonatal studies. In a systematic review of studies on pregnant women the CFR was 33.73 %. The adverse foetal outcomes included miscarriage, stillbirth, and intrauterine death associated with maternal death. Since Lassa fever significantly affects neonates, children, and pregnant women, developing a safe and effective, single-dose vaccine for these high-risk populations is vital. Currently, there are four clinical trials assessing Lassa virus vaccines. Only one of these trials is enrolling children aged ≥18 months, and exclude pregnant and breast-feeding women. It is essential that pregnant and breast-feeding women and young children are included in clinical trials that incorporate robust safety surveillance and risk mitigation measures. In our review, potential approaches to address the specific gaps in the areas of diagnosis, management, and prevention of Lassa fever in these specific populations, such as disease surveillance systems and vaccine development, were identified. A comprehensive strategy with investment focused on addressing specific knowledge gaps will be essential in protecting the health of these specific populations in Lassa virus endemic regions.

Infants, Lassa fever, Lassa vaccine, Maternal immunization, Pediatrics, Pregnancy
0264-410X
Chaudhary, Manu
0a4c119e-b174-4ed3-8614-b0d0c9375238
Cutland, Clare L.
f2564b35-6a18-4ea8-875c-d499281cff1c
Bonet, Mercedes
5a97afe0-c640-42aa-ba64-9b2dc77903be
Gentile, Angela
48ac0d8a-41c0-4fba-9310-867240865daa
Jones, Christine E.
48229079-8b58-4dcb-8374-d9481fe7b426
Marshall, Helen S.
189f2635-7c43-49de-9aa1-fd161b733938
Stergachis, Andy
e8564b96-1fbf-44a6-94ed-65055ae5c140
Voss, Gerald
9e093c06-6535-4933-8666-16a1842d316d
Darko, Delese Mimi
d5d44ddf-2e9a-4d46-8b87-18aa7066ddcf
Sevene, Esperanca
3808ff46-2e2f-4648-b33a-5d7246d3d3ad
Hyde, Terri
0e5b1af2-0195-41d9-979c-818b0a0a79a9
Fairlie, Lee
d259095e-825a-4d7d-aece-91adfc474ecb
Kampmann, Beate
d77ddb9c-c3c5-4245-ae0d-698b1ab2c4b8
Everett, Darcie
d1b8b61b-9770-46a7-be1e-212cb77ad896
Munoz, Flor M.
bf16729d-c634-4bb5-aa84-043baed6a855
Chaudhary, Manu
0a4c119e-b174-4ed3-8614-b0d0c9375238
Cutland, Clare L.
f2564b35-6a18-4ea8-875c-d499281cff1c
Bonet, Mercedes
5a97afe0-c640-42aa-ba64-9b2dc77903be
Gentile, Angela
48ac0d8a-41c0-4fba-9310-867240865daa
Jones, Christine E.
48229079-8b58-4dcb-8374-d9481fe7b426
Marshall, Helen S.
189f2635-7c43-49de-9aa1-fd161b733938
Stergachis, Andy
e8564b96-1fbf-44a6-94ed-65055ae5c140
Voss, Gerald
9e093c06-6535-4933-8666-16a1842d316d
Darko, Delese Mimi
d5d44ddf-2e9a-4d46-8b87-18aa7066ddcf
Sevene, Esperanca
3808ff46-2e2f-4648-b33a-5d7246d3d3ad
Hyde, Terri
0e5b1af2-0195-41d9-979c-818b0a0a79a9
Fairlie, Lee
d259095e-825a-4d7d-aece-91adfc474ecb
Kampmann, Beate
d77ddb9c-c3c5-4245-ae0d-698b1ab2c4b8
Everett, Darcie
d1b8b61b-9770-46a7-be1e-212cb77ad896
Munoz, Flor M.
bf16729d-c634-4bb5-aa84-043baed6a855

Chaudhary, Manu, Cutland, Clare L., Bonet, Mercedes, Gentile, Angela, Jones, Christine E., Marshall, Helen S., Stergachis, Andy, Voss, Gerald, Darko, Delese Mimi, Sevene, Esperanca, Hyde, Terri, Fairlie, Lee, Kampmann, Beate, Everett, Darcie and Munoz, Flor M. (2024) Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine, 43 (Part 1), [126479]. (doi:10.1016/j.vaccine.2024.126479).

Record type: Article

Abstract

Lassa fever is a serious epidemic viral disease in West Africa affecting an estimated 2 million people annually with about 5000–10,000 deaths, although supporting data is sparse. Lassa fever significantly affects neonates, children, and pregnant women, however, comprehensive data on its impact in these populations are lacking. We reviewed the available literature on Lassa fever to assess its prevalence and impact in these populations and implications for vaccine development. Clinical features in children were similar to those observed in adults, with complications such as bleeding. Altered mental status, anasarca (swollen baby syndrome), bleeding, and poor urine output were risk factors for death. The case fatality rate (CFR) in 16 paediatric studies ranged from 6 % to 63 % and was 66.7 % and 75.0 % in two neonatal studies. In a systematic review of studies on pregnant women the CFR was 33.73 %. The adverse foetal outcomes included miscarriage, stillbirth, and intrauterine death associated with maternal death. Since Lassa fever significantly affects neonates, children, and pregnant women, developing a safe and effective, single-dose vaccine for these high-risk populations is vital. Currently, there are four clinical trials assessing Lassa virus vaccines. Only one of these trials is enrolling children aged ≥18 months, and exclude pregnant and breast-feeding women. It is essential that pregnant and breast-feeding women and young children are included in clinical trials that incorporate robust safety surveillance and risk mitigation measures. In our review, potential approaches to address the specific gaps in the areas of diagnosis, management, and prevention of Lassa fever in these specific populations, such as disease surveillance systems and vaccine development, were identified. A comprehensive strategy with investment focused on addressing specific knowledge gaps will be essential in protecting the health of these specific populations in Lassa virus endemic regions.

Text
1-s2.0-S0264410X24011617-main - Version of Record
Available under License Creative Commons Attribution.
Download (1MB)

More information

Accepted/In Press date: 22 October 2024
e-pub ahead of print date: 1 November 2024
Published date: 1 November 2024
Keywords: Infants, Lassa fever, Lassa vaccine, Maternal immunization, Pediatrics, Pregnancy

Identifiers

Local EPrints ID: 497424
URI: http://eprints.soton.ac.uk/id/eprint/497424
ISSN: 0264-410X
PURE UUID: b4bce15b-5dda-4eeb-9483-e84fdfabc16f
ORCID for Christine E. Jones: ORCID iD orcid.org/0000-0003-1523-2368

Catalogue record

Date deposited: 22 Jan 2025 17:47
Last modified: 20 Feb 2025 02:53

Export record

Altmetrics

Contributors

Author: Manu Chaudhary
Author: Clare L. Cutland
Author: Mercedes Bonet
Author: Angela Gentile
Author: Helen S. Marshall
Author: Andy Stergachis
Author: Gerald Voss
Author: Delese Mimi Darko
Author: Esperanca Sevene
Author: Terri Hyde
Author: Lee Fairlie
Author: Beate Kampmann
Author: Darcie Everett
Author: Flor M. Munoz

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×